Kornimate/medical-research-clean huggingface dataset:
hemostasis and inflammation in covid-19 patients with venous and arterial thrombotic complications

Conditions: Venous Thromboembolism; covid19; Thrombosis

Summary: the study is aimed at assessing the role of the activity of high-risk markers of thrombotic events (mcp-1, mip1α, ip-10, phosphatedylserine, calreticulin) on the development of thrombotic complications in patients with covid -19.

the study is aimed at assessing the role of the activity of high-risk markers for thrombotic events (monocytic chemoattractant protein 1 (mcp-1), macrophage inflammatory protein 1α (mip1α), interferon-induced gamma protein-10 (ip-10), platelet apoptosis markers (phosphatedylserine, calreticulin) on the development of thrombotic complications in patients with covid -19. the study will include 150 patients of similar age, gender, and ethnicity, and they will be divided into three groups: group i: 50 patients with confirmed coronavirus infection without thrombotic complications; group ii: 50 patients with confirmed coronavirus infection with thrombotic complications confirmed by ultrasonography without the use of pharmacomechanical prophylaxis of vte; group iii: 50 patients with confirmed coronavirus infection with ultrasound-confirmed thrombosis of the deep and saphenous veins of the lower extremities using pharmacomechanical prophylaxis of vte

Eligibility criteria:
inclusion criteria: * men or women over 18 years of age with a new coronavirus infection, confirmed by polymerase chain reaction (pcr) studies and chest ct. exclusion criteria: * men or women under 18 years of age; active cancer or a remission period of less than 5 years; decompensated somatic pathology; pregnancy or breastfeeding in women.

Keywords: venous thromboembolism vte thrombotic events coronavirus covid-19 hemostasis platelet function
clinical trial study about human adipose-derived stem cells in the liver cirrhosis

Conditions: Liver Cirrhosis

Summary: the aim of the investigators study was to investigate the safety and efficacy of autologous adscs for the clinical treatment of liver cirrhosis.

one milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.

Eligibility criteria:
inclusion criteria: 1. liver cirrhosis investigators with age 20 to 80 years (both inclusive). 2. investigators without mandatory communicable disease (hbv, hcv, hiv, syphilis) 3. investigators without rare disorder 4. coagulation normalities 5. investigators without autoimmune disorder 6. investigators without acquired immune deficiency syndrome 7. investigators without cancer 8. investigators bmi \> 15 exclusion criteria: 1. pregnant women 2. investigators with acute stroke in one month and unconsciousness 3. investigators with acute myocardial infarction or acute heart failure 4. investigators with serious liver dysfunction and coagulation dysfunction and ascites mild higher 5. investigators with acute respiratory failure or pneumonia 6. kidney failure: bun \> 50 7. anemia: hematocrit \< 25 8. investigators diagnosed with liver cancer or liver metastatic carcinoma 9. investigators with liver abscess 10. investigators with acute hepatitis 11. investigators with acute infective 12. liver cirrhosis patients with hbv or hcv 13. investigators diagnosed with carcinoma and receiving treatment 14. investigators with schizophrenia or melancholia 15. investigators received serious surgical operations in 3 months 16. investigators unable to control hypertension (sbp \> 180 mmhg, dbp \> 110 mmhg) or diabetes (ac sugar \> 200 mg/dl) 17. others can't fit into the trial evaluate by investigator
evaluation of case management to improve the outpatient care of alcohol-related disorders

Conditions: Alcohol-related Disorders

Summary: the purpose of this study is to disseminate and transfer the comprehensive quality management interventions (cqm) for alcohol-related disorders in primary care developed during the first funding phase into routine care. the two steps are (1) to optimize the cqm approach and (2) to investigate the dissemination and transfer into routine care in a randomized controlled trial.

in the first funding phase the project aqah ("ambulantes qualitätsmanagement alkoholbezogener störungen in der hausärztlichen praxis"-"comprehensive quality management for alcohol-related disorders in primary care") systematically investigated three issues: (1) the outpatient care system and evidence-base for screening, diagnosis and treatment was examined; it developed (2) a comprehensive quality management system (cqm) consisting of documentation material, a pathway of care and evidence-based practice guidelines; (3) the effects of the cqm on the detection and treatment of alcohol-related disorders were investigated in a randomized controlled pre-post design and the results show positive effects of the cqm. in the second funding phase (a 3 year bi-center project) the purpose is now to disseminate and transfer the cqm into routine care. the two steps are (1) to optimize the cqm approach and (2) to investigate the dissemination and transfer into routine care in a randomized trial. (1) the paper-based aqah-practice guidelines are transformed into an interactive electronic version with online patient documentation and evaluation, decision support measures as well as links to specialists and an e-learning tool. (2) after pilot testing in the aqah-study-networks, an active transfer to the greater regions of südbaden and südwürttemberg will be performed in a parallel group cluster randomized controlled trial with gp practices as unit of randomization. outcome data will be collected concerning the acceptance of the system and the quality of care delivered. comparison(s): (1) use of the interactive electronic version of the cqm for alcohol-related disorders with a special training for general practitioners, compared to (2) use of the cqm with additional education for the whole practice team and organizational re-structuring advice, compared to (3) a control group who uses the cmq without any special training.

Eligibility criteria:
inclusion criteria: * general practitioner * possibility to use broad-band internet exclusion criteria: * none

Keywords: quality of health care primary health care education e-learning alcohol-related disorders
incremental dialysis decision model based on expert-guided machine learning

Conditions: End-stage Renal Disease

Summary: this observational prospective study combined clinical expert knowledge with machine learning to develop and validate a predictive model for incremental hemodialysis decision-making. the aim of the predictive model is to assist clinicians in developing individualized incremental dialysis treatment plans to optimize patient outcomes.

by collecting patients' clinical and biochemical parameters and combining them with experts' judgments of dialysis timing and frequency, the model can dynamically assess patients' risk of needing to increase the frequency of dialysis, thus assisting physicians in formulating individualized incremental dialysis regimens to optimize dialysis outcomes and improve patients' prognosis.

Eligibility criteria:
inclusion criteria: 1. new hemodialysis patients (apr 2010-jun 2024), started within 3 months, including transfers. 2. age ≥18, stable hemodialysis \>6 months. exclusion criteria: 1. incomplete/unreliable data. 2. twice-weekly palliative dialysis. 3. no baseline urine output or ≤200 ml/24h. 4. liver disease, heart failure, or severe comorbidities.

Keywords: machine learning expert knowledge interpretability incremental hemodialysis decision model
promotion of active lifestyle in thromboembolism patients

Conditions: Pulmonary Thromboembolism

Summary: patients who have suffered a pulmonary thromboembolism used to reduce their activity levels because of the symptoms and the fear to suffer other pulmonary thromboembolism. these patients often have sequelae after the hospitalization that previous studies have associated with a lack of physical activity. the main objective of this research is to investigate the efficacy of a rehabilitation program for promotion higher activity levels in quality of life and self-perceived discapacity of thromboembolism patients.


Eligibility criteria:
inclusion criteria: * patients of both sexes. * agreed to participate. * thromboembolism patients meeting the diagnosis criteria for this disease. exclusion criteria: * neurological or orthopaedic pathologies that limited voluntary movement. * cognitive impairment that prevented them from understanding and answering the questionnaires. * patients suffering from a previous pulmonary thromboembolism. * patients who don´t understand spanish language

Keywords: pulmonary thromboembolism rehabilitation activity promotion
intensive tdcs for mdd: feasibility study

Conditions: Major Depressive Disorder

Summary: this will be a prospective, open-label, single-arm study to determine the safety and feasibility of an intensive treatment of transcranial direct current stimulation (tdcs) for major depressive disorder (mdd). participants will be age 18-65 with a diagnosis of unipolar mdd. participants will receive an intensive treatment of tdcs over a 10-day treatment period and complete follow-up assessments at the end of treatment, 1, and 4 weeks post-treatment.

this will be a prospective, open-label, single-arm study to determine the safety and feasibility of an intensive treatment of transcranial direct current stimulation (tdcs) for major depressive disorder (mdd). secondary objective is to gather preliminary data on the clinical effects of the protocol. after assessment and inclusion into the study, participants will receive up to 50 tdcs sessions over 10 days. study procedures: daily assessments: brief questions before and after each tdcs session to evaluate potential adverse events as well as a verbal rating scale for pain. questionnaires : a battery of mood questionnaires will be completed to inform findings regarding clinical effects of the treatment. cognitive measures: a short cognitive assessment will be completed to inform findings regarding cognitive safety of the treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of major unipolar depression for at least 4 weeks meeting the criteria of the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) * age between 18 to 65 * minimum score of 17 on the grid-hamilton depression rating scale (grid-hamd) exclusion criteria: * bipolar disorder, * psychosis * active substance use disorder (in the last 3 months) * personality disorder * neurocognitive disorder * high risk of suicide * major comorbid medical or neurological condition * pregnancy medical contraindications to tdcs: * ferromagnetic material in the skull * defect in the bone substance of the skull * dermatological condition (e.g. eczema, psoriasis, urticaria, dermatitis, acne, hyperhidrosis, folliculitis, rosacea, keratosis, herpes, infectious or neoplastic phenomenon, etc.) * skin lesion on the skull (ex: cuts, abrasions, rash, tattoos on the skull, piercings on the head, etc.)
study to evaluate the pharmacokinetics of velpatasvir in participants with normal renal function and severe renal impairment

Conditions: Hepatitis C Virus

Summary: the primary objective of the study is to evaluate the single-dose pharmacokinetics (pk) of velpatasvir (formerly gs-5816) in participants with severe renal impairment using matched healthy participants as a control group.


Eligibility criteria:
key inclusion criteria: * general good health with stable chronic kidney disease in severe renal impairment group * screening labs within defined thresholds * creatinine clearance must be \< 30 ml/min for severe renal impairment group, and ≥ 90 ml/min for normal renal function group key exclusion criteria: * females who are pregnant or nursing, or males who have a pregnant partner * infection with hepatitis b virus (hbv), hepatitis c virus (hcv) or hiv * history of clinically significant illness (including psychiatric or cardiac) or any other medical disorder that may interfere with participant treatment and/or adherence to the protocol note: other protocol defined inclusion/exclusion criteria may apply.
controlled study of ono-5920 in patients with involutional osteoporosis in japan

Conditions: Involutional Osteoporosis

Summary: the purpose of this study is to evaluate the efficacy and safety of ono-5920 in patients with involutional osteoporosis.


Eligibility criteria:
inclusion criteria: 1. patients with fragility fracture according to the diagnostic criterial for the diagnosis of primary osteoporosis 2. patients having radiographically confirmed vertebral (t4-l4) fractures 3. other inclusion criteria as specified in the study protocol exclusion criteria: 1. patients having secondary osteoporosis or another condition that presents low bone mass 2. patients having findings on x-ray that affect evaluation of vertebral fracture 3. patients that have been administered bisphosphonate derivatives 4. other exclusion criteria as specified in the study protocol

Keywords: ono-5920, osteoporosis, bisphosphonate
a cognitive self-management intervention for persons with multiple sclerosis: adapting web-based technology

Conditions: Multiple Sclerosis

Summary: development and pilot testing of a cognitive self-management intervention for persons with multiple sclerosis (pwms) emphasizing physical activity (pa) delivered via web-based video conference.

the primary objective of this study is to develop and pilot test an innovative cognitive self-management intervention for pwms delivered via web-based video conferencing. data derived from interviews will be used to guide the adaptation of stuifbergen's 8-week memory, attention, and problem-solving skills in ms (mapss-ms) intervention to be delivered via web-based video conferencing. the adapted mapss-ms intervention will be feasibility tested in small groups of pwms. outcome variables include: (1) neurocognitive function assessed using the nih toolbox®, a comprehensive set of psychometrically sound neuro-behavioral measures that quickly assesses cognitive functions using an ipad, (2) objective pa and sleep using actigraph™ accelerometers, (3) self-reported sleep, depression, and fatigue using the patient-reported outcome measurement information system (promis), and (4) ms specific self-management using the multiple sclerosis self-management scale (mssm). community-residing pwms, age 21 to 70, will be recruited from central texas to participate in phase 1 interviews (n=5) and phase 2 pilot testing (n=20) of the adapted version of the 8-week mapss-ms cognitive self-management intervention emphasizing pa delivered via web-based video conferencing. in phase 2 pilot testing (n=20), an intervention group (n=10) will be compared to an "enhanced usual care" control group (n=10).

Eligibility criteria:
inclusion criteria: * diagnosis of clinically definite ms documented by their healthcare provider * age 21 to 70 * capable of understanding and complying with the study protocol * able to read and write in english * stable disease at the time of entry into the study (relapse free for at least 90 days) * willing to participate in an 8-week study promoting physical activity, ms self-management and compensatory cognitive strategies, and data collection * have subjective concerns about their cognitive functioning (score ≥ 10 on the 20-item perceived deficits questionnaire) * any gender * any ethnic/racial group exclusion criteria: * currently pregnant or plan to be * diagnosed with cardiovascular or respiratory disease, other medical causes of dementia or other neurological disorders that may impact cognition or emotions * evidence of major psychiatric disorder * major functional limitations that preclude them from participating in the study

Keywords: cognitive function physical activity self-management
flexi band resistance training versus ems exercise in patients with the diagnosis of malignant diseases

Conditions: Cancer; Cancer Cachexia; Inflammation; Muscular Atrophy

Summary: the purpose of this study is to investigate the effects of a 12-week flexi band resistance training program compared to different whole-body electromyostimulation (wb-ems) exercise programs on muscle strength, body composition (in particular muscle mass), cardiorespiratory fitness, inflammation, and patient-reported subjective outcomes (e.g. quality of life, fatigue, performance status) in patients with malignant disease undergoing curative or palliative anti-cancer treatment.


Eligibility criteria:
inclusion criteria: * malignant disease (solid or hematological cancer): head and neck cancer, colorectal carcinoma, small intestinal cancer, gastric cancer, oesophageal cancer, pancreas carcinoma, liver cell carcinoma, cholangiocarcinoma, lung cancer, breast cancer, cervix cancer, ovarian cancer, prostate cancer, renal cell carcinoma, malignant melanoma, patients with leukaemia and malignant lymphomas or graft-versus-host-disease after bone marrow transplantation * ongoing or planned curative or palliative anti-cancer therapy * ecog-status 0-2 exclusion criteria: * simultaneous participation in other nutritional or exercise intervention trials * bone metastases with high fracture risk * cardiovascular disease * use of anabolic medications * epilepsy * severe neurological or rheumatic diseases * skin lesions in the area of electrodes * energy active metals in body * pregnancy * acute vein thrombosis

Keywords: cancer cachexia muscular strength resistance training body composition muscle mass physical exercise nutrition whole-body electromyostimulation
prevalence of wild-type ttr cardiac amyloidosis in patients with polyneuropathy of unknown cause.

Conditions: Polyneuropathy; Amyloidosis

Summary: to investigate to what extent chronic axonal length-dependent polyneuropathy (cap) and/or small-fiber neuropathy (sfn) is part of early non-cardiac manifestations of wild-type ttr cardiac amyloidosis (wtttr-ca). consequently, explore whether this could ultimately lead to faster diagnosis and clinical outcome of wild-type ttr cardiac amyloidosis (wtttr-ca).

patients with chronic axonal length-dependent polyneuropathy (cap) and/or small-fiber neuropathy (sfn) without well-defined cause will be recruited after a neurological standard routine work-up with ncs (nerve conduction study) test, emg, and sudoscan®, previously performed at the neurology department of uz-brussel in normal clinical setting. all participants will be invited to the neurology and cardiology department for one visit on one day, for the following assessments: following exams will be performed: * assessment of symptoms, severity, and duration of the polyneuropathy and the use of ntss-6 and compass31 score for mapping somatosensory and autonomic symptoms * evaluation of objective polyneuropathy signs, using following scales: mpnd, nis * kansas city cardiomyopathy questionnaire (kccq) * electrocardiogram (ecg) * echocardiography the following retrospective data from the medical file will be analyzed: * assessment of medical history, medical treatment, and demographic data * assessment of laboratory results (and, if applicable, other exams) extracted from the medical file and previously performed in the context of polyneuropathy workup * assessment of previously performed ncv/emg data and sudoscan®, extracted from the medical file of the participants.

Eligibility criteria:
inclusion criteria: * patients with chronic axonal length-dependent polyneuropathy (cap) and/or small-fiber neuropathy (sfn) without well-defined etiology. * age: \>= 60 years * male and female gender * written informed consent exclusion criteria: * known cause of polyneuropathy * other types of peripheral neuropathy than chronic axonal length-dependent polyneuropathy (cap) and/or small-fiber neuropathy (sfn). * patients younger than 60 years
fecal microbiota transplantation (fmt) for severe acute pancreatitis(sap)

Conditions: Acute Pancreatitis; Intestinal Bacteria Flora Disturbance; Intestinal Dysfunction; Fecal Microbiota Transplantation

Summary: severe acute pancreatitis is an acute and rapid progress of the digestive system disease.most patients with severe pancreatitis associated with intestinal mucosal barrier dysfunction.intestinal microflora,an important part of the intestinal mucosal barrier, play an important role in the development process in the course of severe acute pancreatitis. at this stage of the study that infection of pancreas and other organs is the leading cause of death in patients with severe acute pancreatitis，and the main pathogens from intestinal micro-organisms， but the intestinal flora changes did not be mentioned. fecal microbiota transplantation that has been used for treatment of inflammatory bowel disease and clostridium difficile infection may be a new technology for regulation of intestinal mucosal dysfunction and intestinal flora unbalance.

patients with acute pancreatitis will be assessed depending on apache ii and ct score and all of them also will be separated into two parts depending on acceptation or refusal of fmt. blood specimens from patients will be collected to analysis inflammatory factors，and fecal microbiota samples will be detection.

Eligibility criteria:
inclusion criteria: 1. the diagnosis of acute pancreatitis: elevated serum amylase and/or lipase levels (more than 3-fold the upper reference limit) and evidence of pancreatitis on computed tomography (ct) of the abdomen; 2. no chronic diseases of the digestive system ; 3. no chronic diseases of the urinary system; 4. no chronic metabolic disease; 5. no chronic disease of immune system 6. no chronic disease of mental disease 7. no acute intestinal disease; taking antibiotics anti-inflammatory drugs and history of probiotics for one month; 8. no use of addictive drugs and immune inhibitors exclusion criteria: 1. not to match the standard of ap 2. with chronic diseases of the digestive system; 3. with chronic diseases of the urinary system; 4. with chronic metabolic disease; 5. with chronic disease of immune system 6. with chronic disease of mental disease 7. with acute intestinal disease; taking antibiotics anti-inflammatory drugs and history of probiotics for one month;pregnancy and lactation women 8. with use of addictive drugs and immune inhibitors 9. exceed the age limits

Keywords: acute pancreatitis intestinal mucosal barrier fecal microbiota transplantation
clinical study of hrs-2129 for postoperative analgesia in orthopaedics

Conditions: Postoperative Pain in Orthopaedics

Summary: the study is being conducted to evaluate the safety, and efficacy of hrs-2129 for postoperative analgesia in orthopaedics. to explore the reasonable dosage of hrs-2129 for postoperative analgesia in orthopaedics.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide a written informed consent 2. subjects requiring elective orthopedic surgery 3. conform to the asa physical status classification exclusion criteria: 1. subjects with a history of severe allergies 2. subjects with nervous system disease 3. subjects with a history of mental illness 4. subjects with abnormal liver and renal function 5. subjects with poorly controlled hypertensive or hypotensive 6. qtc：\>450ms（male），\>470ms（female） 7. subjects who screened positive for substance abuse 8. history of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) 9. the investigators determined that other conditions were inappropriate for participation in this clinical trial